Replies to post #254101 on Biotech Values

[WorstLuck]

Moreover, at the current valuation ENTA could receive buyout interest from a company who had little or no interest in ENTA’s pipeline and merely wanted to raise capital cheaply.

Such an offer would be for less than the present value of the HCV franchise ipso facto. Unlikely to get interest from the board and would not affect the share price unless it was hostile. Perhaps what you want, IDK.

[alertmeipp]

At this price, I wish ENTA could just start a formal strategic review and shop itself to the highest bidder. There is clearly some trust issues with the management from the market, the market is assigning less and less value to its pipeline as they make progress.

The crazy thing is if they conclude it this year, worst case we probably get a 3x return from here. Best case, a lot higher.

Maybe I should try to get a hold of management and suggest that. ;)